Biotechnology firm Immunomic Therapeutics has partnered with EpiVax and PharmaJet to develop a vaccine candidate against Covid-19 infection.
Immunomic will leverage its UNITE platform, along with its partners’ immunology and vaccine delivery expertise to rapidly create a nucleic acid vaccine candidate.
Previously, UNITE platform was used to develop vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and also SARS, which is similar to the novel coronavirus.
Immunomic Therapeutics CEO Dr William Hearl said: “We believe that our UNITE platform, which has shown promising results in infectious disease applications, is well-suited to develop novel vaccines for coronaviruses. “To rapidly advance our Covid-19 programme, we